Co-expression of Cox-2, C-met and Beta-catenin in Cells Forming Invasive Front of Gallbladder Cancer
Overview
Affiliations
Purpose: Gallbladder cancer is a malignancy with poor prognosis, predominantly resulting from invasion and metastasis. Our previous studies have demonstrated that prostaglandin E(2) (PGE(2)), generated by cyclooxygenase 2 (Cox-2), transactivates epidermal growth factor receptor (EGFR), c-Met and beta-catenin; thus, enhancing colon cancer cell growth and invasiveness in vitro. To determine whether these findings are applicable to clinical conditions, we examined the expression and cellular localization/co-localization of Cox-2, c-Met, beta-catenin, EGFR and c-erbB2 in gallbladder cancer.
Materials And Methods: Thirty-five specimens of invasive gallbladder cancer, 8 in situ carcinoma and 7 adenoma specimens were immunostained with specific antibodies against Cox-2, c-Met, beta-catenin, EGFR and c-erbB2. The cellular distribution, localization and colocalization were examined, and the signal intensities quantified in: a) the central area of gallbladder cancer and b) cancer cells forming the invasive front.
Results: Cox-2, c-Met, beta-catenin, c-erbB2 and EGFR were over-expressed in 80, 74, 71, 62 and 11% of invasive gallbladder cancers, respectively. beta-catenin was expressed in 80% of non-malignant specimens, exclusively in the cell membrane, while the cancer specimens showed cytoplasmic and/or nuclear staining. Significantly higher Cox-2, c-Met and beta-catenin expressions were present in cancer cells of the invasive front than in the tumor central areas (p<0.001), and these expressions were significantly (p=0.01) associated with the invasion depth. Co-expressions of Cox-2, c-Met, beta-catenin and c-erbB2 were present in 42% of the specimens in cancer cells forming the invasive front.
Conclusion: The overexpressions, and often co-localizations, of Cox-2, c-Met and beta-catenin in cancer cells forming the invasive front indicate their local interactions and important roles in invasion.
Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers.
Lu W, Aihaiti A, Abudukeranmu P, Liu Y, Gao H Mol Cell Biochem. 2024; 480(2):1225-1239.
PMID: 38963615 DOI: 10.1007/s11010-024-05057-2.
Kim Y, Jee S, Kim H, Paik S, Choi D, Yoo S Oncologist. 2024; 29(8):e1051-e1060.
PMID: 38709907 PMC: 11299936. DOI: 10.1093/oncolo/oyae076.
Grizzi G, Ghidini M, Ratti M, DErcole M, Tanzi G, Abbiati A J Pers Med. 2023; 13(6).
PMID: 37373946 PMC: 10304896. DOI: 10.3390/jpm13060957.
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.
Sturm N, Schuhbaur J, Huttner F, Perkhofer L, Ettrich T Cancers (Basel). 2022; 14(22).
PMID: 36428670 PMC: 9688543. DOI: 10.3390/cancers14225580.
Neogi K, Murumkar P, Sharma P, Yadav P, Tewari M, Karunagaran D Transl Oncol. 2022; 19:101395.
PMID: 35325837 PMC: 8938628. DOI: 10.1016/j.tranon.2022.101395.